Clinical Trial Update: Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab as first-line therapy for advanced non-small cell lung cancer complicated by COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianjin Chest Hospital | Conditions: NSCLC With COPD | Phase 2 | Status: UNKNOWN